Androgens are considered to have immunomodulatory effects but their cellular mechanisms of action remain largely unknown. In the present study we prospectively analyzed the serial effects of androgen-replacement therapy on both the distribution of peripheral blood lymphocytes, monocytes and dendritic cells as well as on the production of interleukin (IL)-1 , IL-6 and tumor necrosis factor (TNF ) inflammatory cytokines by circulating monocytes and CD33 myeloid, CD16 and plasmacytoid dendritic cell subsets, the most potent antigen-presenting cells (APCs) in type-2 diabetic men with partial androgen deficiency. Analyses were performed before therapy and at 1, 3, 6 and 12 months after treatment with 150 mg testosterone enanthate every 2 weeks in a group of 13 type-2 diabetic men. Our results show for the first time that testosterone-replacement therapy is associated with a reduction or complete abrogation of spontaneous ex vivo production of IL-1 , IL-6 and TNF by APCs. Meanwhile, the in vitro production of inflammatory cytokines by these cells after stimulation with lipopolysaccharide plus recombinant human interferon-remained unchanged, suggesting that APCs preserve their constitutive machinery to produce inflammatory cytokines under androgen treatment. These results confirm and extend previous observations about the anti-inflammatory effects of androgen therapy on APCs in a new, previously unexplored model of androgen deficiency; namely, aging type-2 diabetic men. A decreased production of inflammatory cytokines by APCs might have important consequences for sex differences in susceptibility to autoimmune diseases, inflammatory response to injury and atheromatosis.
Introduction
Aging in men is associated with a progressive decrease in serum testosterone levels and an increase in the prevalence of hypogonadism (Harman et al. 2001 , Feldman et al. 2002 . Although the age-related decrease in testosterone levels is independent of health status (Harman et al. 2001) , in diseases such as diabetes mellitus androgen deficiency could be exacerbated since lower testosterone values have been reported in older type-2 diabetic men than in age-matched non-diabetic individuals (Barrett-Connor et al. 1990 , Anderson et al. 1994 . The partial androgen deficiency detected in aging men has been related to the development of multiple symptoms and signs, and it has been shown that androgen-replacement therapy may induce improvements of lean body mass (Tenover 1992 , Snyder et al. 1999 , Kenny et al. 2001 , bone mineral density (Kenny et al. 2001) , libido (Hajjar et al. 1997) , sexual function (Kunelius et al. 2002) , grip strength (Sih et al. 1997 ) and spatial cognition (Janowski et al. 1994) , together with a decrease in body fat mass (Snyder et al. 1999 , Kenny et al. 2001 . Nevertheless, present information about the benefits and risks of testosterone replacement is limited and there is consensus about the need for further studies in which the effects of androgen replacement in aging males can be evaluated (American Society for Reproductive Medicine 2004 , Snyder 2004 .
In line with this, little is known about the cellular effects of androgen-replacement therapy on the immune response in men (Jacobson & Ansari 2004) . Further insight into this field may contribute to the understanding of the mechanisms involved in the beneficial effects of androgens on the immune system (Malkin et al. 2003 , Cutolo et al. 2004 and their protective effect against the development of autoinmune diseases (Bizzarro et al. 1987 , Fitzpatrick et al. 1991 , Bebo et al. 1998 , Gylling et al. 2003 . In fact, previous studies have indicated that gender-associated differences in susceptibility to autoimmune diseases may be related to sex differences in cytokine secretion by circulating immunocompetent cells (Bebo et al. 1999 , Liva & Voskuhl 2001 .
Here we report a prospective study on the short-and long-term effects of androgen-replacement therapy on the circulating inflammatory cellular compartment of the immune system in a group of type-2 diabetic men with partial androgen deficiency followed over 1 year of treatment.
Materials and Methods

Patients and control subjects
A total of 13 consecutive men older than 55 years (range, 55-73 years; mean S.E.M. 64 2 years) with type-2 diabetes were enrolled in the study. Diagnosis of diabetes was established either from the patient's history or according to the American Diabetes Association criteria (American Diabetes Association 1998) in the case of patients with recent onset of diabetes. Type-2 diabetes was diagnosed on the basis of a history of initial successful treatment with oral hypoglycemic agents as well as by assessment of residual -cell function, measuring C-peptide serum values. At the moment of entering the study the duration of diabetes ranged between 2 and 22 years. Four patients were treated with insulin, five with insulin plus oral hypoglycemic agents, and four with oral hypoglycemic agents. None of the patients had clinically evident atherosclerotic complications and all were ambulatory. Inclusion criteria were: (1) a positive history of fertility (indicating previous testicular health); (2) a healthy partner (to prevent answers on the questionnaire used to obtain the clinical criteria of andropause from being influenced by exogenous factors); (3) absence of clinically overt hypogonadism, or hepatic, cardiac or renal insufficiency and (4) lack of ingestion of drugs that could induce hypogonadism. Exclusion criteria included diseases in which treatment with testosterone should be contraindicated, such as prostate cancer, active benign prostatic hyperplasia, breast carcinoma, sleep apnea, or chronic lung disease.
In addition to diabetic patients, eight healthy men with neither diabetes mellitus nor any of the components of the metabolic syndrome, of similar age (range, 52-76 years; mean S.E.M. 64 3 years), weight and body mass index to the diabetic patients, were studied in parallel as a control group (Table 1) . Control individuals were recruited in the same outpatient clinic as the diabetic patients. The patients and controls did not have infection, inflammatory or allergic diseases nor were they receiving treatment with glucocorticoids or nonsteroidal antiinflammatory drugs, and they all gave written informed consent prior to entering the study. The study protocol was approved by the local research ethics committee of the University Hospital of Salamanca, Spain.
Clinical and hormonal criteria of partial androgen deficiency
Clinical criteria to define partial androgen deficiency were established on the basis of a specific questionnaire consisting of eight items related to androgen deficiency, which has been previously described in detail . This questionnaire had a sensitivity of 90% and a specificity of 74% when applied to aging type-2 diabetic patients (Corrales et al. 2003) . The questionnaire was applied by the same person in all but one case and all patients had positive questionnaires and hence met the clinical criteria of androgen deficiency. Androgen deficiency was confirmed using a biochemical criterion consisting of a total testosterone serum level of c3·4 ng/ml, according to its normal concentrations in a group of healthy young fertile controls (Corrales et al. 2000) . This figure is similar or identical to the level used to define biochemical andropause by authorities in the field (Kaufman & Vermeulen 1997) or in recent epidemiological studies (Harman et al. 2001) . In a few patients who met the clinical criteria for androgen deficiency but displayed total serum testosterone values marginally higher than 3·4 ng/ml, the criterion of free testosterone values of c11 pg/ml, which represent the lower end of the normal range in young adults, was used. In agreement with our recommendations (Nieschlag et al. 2004 ) symptoms were always considered in the context of the full clinical picture in relation to testosterone serum levels; thus partial androgen deficiency was considered when a patient met both the clinical and biochemical criteria defined above.
Hormone and other laboratory measurements
Blood samples were obtained for all laboratory measurements simultaneously between 8:00 to 9:00 AM. Plasma glucose levels were assayed by a glucose oxidase method. Total and free testosterone concentrations were measured by solid-phase [ 125 I]RIA (Coat-a-Count; DPL, Los Angeles, CA, USA) and luteinizing hormone (LH), follicle-simulating hormone (FSH), and prolactin levels were determined with a RIA (RIA-gnost; CIS Bio International, Gif-sur-Yvette, France), as previously described in detail (García-Díez et al. 1983 , Corrales et al. 2000 . The RIA-React (CIS Bio International) and the INS-Irma (Biosource, Nivelles, Belgium) RIAs were used to measure prostate-specific antigen (PSA) and insulin serum levels, respectively. C-peptide levels were determined using a commercial RIA (C-PEP; Biosource). HbA 1 c (Menarini Diagnostics, Florence, Italy) and fructosamine (Fruc; Roche Diagnostics) were measured using commercial kits.
The sensitivities and the intra-and interassay coefficients of variation of the methods were: 0·04 ng/ml, 5·7% and 6·7%, respectively, for total testosterone; 0·15 pg/ml, 5·4% and 8·5% for free testosterone; 0·1 mIU/ml, 2·9% and 3% for LH; 0·1 mIU/ml, 3·4% and 3% for FSH; 2 µIU/ml, 6·9% and 7·8% for prolactin; 0·04 ng/ml, 2·2% and 4·2% for PSA; 1·5 µIU/ml, 6·9% and 8·1% for insulin; 0·04 pmol/ml, 8·2% and 9·3% for C-peptide; 2·5%, 5·2%, and 5·2% for HbA 1 c; 10 µmol/l, 0·9% and 2·9% for fructosamine.
Treatment with testosterone
Diabetic patients meeting the criteria of androgen deficiency were treated with 150 mg intramuscular testosterone enanthate every 15 days for 1 year. They were studied prior to therapy, and at months 1, 3, 6 and 12 of testosterone therapy. On each of these visits, the following laboratory safety tests were performed: complete blood count, blood pressure, PSA levels and liver tests; in addition, symptoms of urinary obstruction were also evaluated. During follow-up, measurements of total and free testosterone levels were performed on day 8 after each injection. Evaluation of treatment compliance was performed by monitoring the decrease in serum LH levels induced by exogenously added testosterone.
Identification and enumeration of peripheral blood (PB) monocyte, dendritic cell (DC) and lymphocyte subsets
Identification and enumeration of PB monocytes, DCs and lymphocytes were performed on EDTAanticoagulated PB samples stained with specific combinations of monoclonal antibodies (mAbs) using a direct immunofluorescence, single-platform flow cytometry technique as previously described . Briefly, 100 µl of a pre-mixed PB sample was placed in two separate tubes and stained for 15 min at room temperature (RT) with the Dendritic Cell Exclusion kit, which contains a mixture of FITC-conjugated anti-CD3, CD14, CD19 and CD56 mAbs (Cytognos, Salamanca, Spain), CD16-phycoerythrin (PE; clone 3 G8; Immunotech, Marseille, France), anti-HLA-DR-peridin in chlorophyll protein (PerCP; clone L243; Becton Dickinson Biosciences, San Jose, CA, USA) and CD33allophycocyanin (clone LeuM9; Becton Dickinson Biosciences) mAb or the LYMPHOGRAM reagent (Cytognos). Then cells were incubated with 2 ml of either Quicklysis (Cytognos) or FACS lysing solution (Becton Dickinson Biosciences) for 10 min at RT. Once this incubation period was finished, the cells stained with the LYMPHOGRAM reagent were centrifuged at 540 g (5 min, RT); following this, the lysing solution was removed, and the cell pellet washed twice in 2 ml PBS (pH 7·6) and resuspended in 0·5 ml PBS. Immediately prior to data acquisition, 100 µl pre-mixed Perfect-Count beads (Cytognos) were added to the other tube. After gentle mixing samples were run on a FACSCalibur flow cytometer (Becton Dickinson Biosciences) using Cell-QUEST software (Becton Dickinson Biosciences). Data acquisition was performed as previously described, collecting information on >10 3 DCs (defined as those cells being of the MHC-II + /lineage /dim+ ) and >10 4 lymphocytes. For data analysis, Paint-A-Gate Pro software (Becton Dickinson Biosciences) was used.
In addition to the monocytes, the following subsets of DCs and lymphocytes were identified: (1) myeloid DCs (CD33 hi ); (2) CD16+ DCs (CD33+, CD14 /dim+ ); (3) plasmacytoid DCs (CD33 /dim+ ; Almeida et al. 1999 Almeida et al. , 2001 ; (4) CD4+/CD8 T cells; (5) CD8+/CD4 T lymphocytes; (6) CD4 /CD8 T cells; (7) CD4+/ CD8+ T lymphocytes; (8) CD4 /CD8+ dim T-cells;
(9) CD4+/CD8 dim+ T cells; (10) CD56+/CD8+ natural killer (NK) cells; (11) CD56+/CD8 NK cells and (12) CD19+ B lymphocytes.
Analysis of cytokine secretion by PB monocytes and DCs
The spontaneous and stimulated secretion of cytokines by monocytes and DCs was analyzed at the single-cell level in heparinized PB samples, using a well-established fourcolor staining technique that combines the specific identification of monocytes and DCs with the measurement of intracellular cytokine production after short-term in vitro culture (Almeida et al. 1999 . Briefly, 500 µl heparin-anticoagulated PB was placed in a tube, to which 100 ng/ml lipopolysaccharide (LPS; from Escherichia coli serotype 055:B5; Sigma) and 10 ng/ml human recombinant interferon (IFN ; Promega) were added for the specific stimulation of PB MHC-II + / lineage cells . Then, 500 µl RPMI 1640 culture medium (BioWhittaker, Walkersville, MD, USA) supplemented with 2 mM -glutamine was added to complete a final volume of 1 ml. In addition, 10 µg/ml brefeldin A (Sigma; Bueno et al. 2001 ) was added to block cytokine secretion by cytokine-producing cells. An unstimulated sample also containing brefeldin A and processed in an identical way in the absence of any exogenous stimuli was used to evaluate spontaneous ex vivo cytokine secretion. Then cells were incubated for 6 h at 37 C in a 5% CO 2 and 95% humidity sterile environment, as previously described in detail (Almeida et al. 1999) . Once this incubation period had ended, the sample was aliquoted into four different tubes (approximately 200 µl/tube) and cells were stained with the Dendritic Cell Exclusion kit, anti-HLA-DR-PerCP and CD33-allophycocyanin. After a gentle mixing, cells were incubated for 15 min in the darkness (at RT), washed in 2 ml PBS, fixed, permeabilized and stained with mAbs directed against different human inflammatory cytokines using the Fix & Perm reagent kit (Caltag, San Francisco, CA, USA) according to the recommendations of the manufacturer. The mAb reagents used to detect intracellular cytokines were as follows: anti-interleukin (IL)-6-PE (clone MQ2-6A3; Pharmingen, San Diego, CA, USA); anti-tumor necrosis factor (TNF )-PE (clone 11; Pharmingen) and anti-IL-1 -PE (clone AS10; Becton Dickinson Biosciences). Isotype-matched negative mAb reagents conjugated with PE were used as negative controls.
Data acquisition and analysis were performed on a FACSCalibur flow cytometer as described above. For data analysis, cytokine production by specific subsets of DCs and monocytes was calculated in terms of both the percentage of positive cells within each cell subset and the mean fluorescence intensity (MFI) obtained for each specific cytokine after subtracting the MFI of the corresponding isotype-matched negative control.
Statistical analyses
Data were analyzed using SPSS software (SPSS 12·0; Chicago, IL, USA). The normal quantile (Normal Q-Q Plot) test was used to assess whether or not data for each variable had a normal distribution. The statistical significance of the differences observed between healthy controls and diabetic men (unpaired samples) was determined using the Student's t and Mann-Whitney U tests for variables with a normal and non-parametric distribution, respectively. The statistical significance of the differences observed between distinct treatment time points in diabetic samples (paired samples) was determined using the non-parametric Friedman and Wilcoxon signed-rank tests. The relationship between plasma hormone values (testosterone, LH and FSH) with antigen-presenting cell (APC) counts (monocytes and DCs) was tested by Spearman correlation analysis. P values (two-tailed) of c0·05 were considered to be associated with statistical significance.
Results
The clinical characteristics of the control subjects and type-2 diabetic men are shown in Table 1 . Both groups had similar anthropometric features but, as expected, exhibited significantly different fasting plasma glucose (P=0·001) and C-peptide (P=0·04) levels. In addition, the diabetic patients had lower serum concentrations of total testosterone (P=0·04) and higher LH levels (P=0·02) than controls. Replacement therapy with testosterone enanthate increased the serum levels of total and free testosterone while the serum values of LH decreased to undetectable levels (Fig. 1 ).
All but one patient completed the 12-month course of testosterone-replacement therapy. During this period, no patient had any adverse cardiovascular or prostatic events. In one patient, testosterone therapy was withdrawn after completing 6 months of treatment due to an increase in his hematocrit value above 52%. In another two cases, a phlebotomy was performed at 6 and 9 months after starting treatment because of a hematocrit value of between 50 and 52%. The mean PSA levels before and after testosterone treatment were 1·4 and 1·8 ng/ml, respectively. No significant differences in weight were detected before testosterone therapy or at the end of treatment (78 14 compared with 76 14 kg, respectively).
Prior to testosterone-replacement therapy, the type-2 diabetic men showed higher white blood cell (Pc0·05) and monocyte (pc0·05) counts, together with increased numbers of CD4 /CD8 lo T cells (Pc0·01) as compared with the control subjects (Table 2 ). In general, testosterone treatment did not induce significant quantitative changes in most of the subsets of white blood cells studied, in either absolute or relative numbers, which remained stable and similar to those found before treatment.
Despite this, some exceptions were noted, including a transient increase in the number of polymorphonuclear leukocytes at month 1 of treatment (P<0·05), as well as both an increase in the number of CD4 /CD8+ T cells (P<0·05) and a decrease in the proportion of CD4+/ CD8 T cells (P<0·05) at the end of therapy (6 and 12 months); these were associated with a transient increase in the percentage of CD56+/CD8 NK cells (1 month of therapy) and a decrease in the percentage of CD56+/ CD8+ NK cells (at 1 month), with respect to the data Figure 1 Serum concentrations of testosterone and LH before (0) and during 12 months of treatment with 150 mg testosterone enanthate administered intramuscularly in 13 type-2 diabetic men. Results are expressed as means S.D. *P<0·05, vs before treatment; **P<0·01 vs before treatment. TT, total testosterone; FT, free testosterone. Table 2 Distribution of monocytes and subsets of lymphocytes and dendritic cells (DCs) in PB samples from type-2 diabetic men with partial androgen deficiency prior to and during testosterone-replacement therapy (TX), as compared to healthy age-matched controls before treatment. In addition, transient increases in the number of CD33 hi myeloid DCs (months 1 and 12 of therapy) and CD123 hi plasmacytoid DCs (month 6) to values significantly higher than those of the controls were also observed during treatment with testosterone (Table 2) . Small percentages of monocytes and DCs capable of spontaneously secreting detectable amounts of proinflammatory cytokines were detected in both the diabetic men and the control group prior to therapy (Table 3) . After testosterone-replacement therapy, the number of PB monocytes capable of spontaneously producing IL-1 , IL-6 and TNF became undetectable both at the first follow-up time point (IL-1 ) and at the end of therapy (IL-6 and TNF ). Likewise, the percentage of CD33 hi myeloid DCs and that of plasmacytoid DCs capable of spontaneously producing IL-6 and TNF also became undetectable during testosterone treatment. In contrast, no major changes were observed with testosterone-replacement therapy in the spontaneous production of proinflammatory cytokines by peripheral blood CD16+ DCs (Table 3) .
Controls
Diabetic patients with partial androgen deficiency
Prior to therapy, CD33 hi myeloid DCs and CD16+ DCs from the diabetic men showed a decreased ability to secrete IL-1 (Pc0·05) after in vitro stimulation with LPS as compared with the control group (Table 4) . Testosterone-replacement therapy was associated with a transient recovery of the percentage of IL-1 -secreting CD33 hi myeloid DCs and CD16+ DCs at months 3 and 12, and month 3 of therapy, respectively. In addition, testosterone-replacement therapy was also associated with a decreased number of TNF -secreting plasmacytoid DCs at month 12.
Interestingly, analysis of the relationship between plasma hormone levels (testosterone, LH and FSH) and cytokine production by different subsets of PB APCs in diabetic men revealed a statistically significant negative correlation between the levels of LH and the percentage Table 3 Spontaneous ex vivo secretion of inflammatory cytokines by peripheral blood monocytes and dendritic cells (DCs) in type-2 diabetic patients with partial androgen deficiency before treatment and after 1, 3, 6 and 12 months of testosterone-replacement therapy (TX), in comparison to control subjects of both monocytes (r 2 = 0·329; P=0·02) and CD16+ DCs (r 2 = 0·311; P=0·03) spontaneously producing IL-6 in untreated patients. In turn, LH serum levels correlated positively with both the mean amount of IL-6 spontaneously secreted per cell (MFI) by CD16+ DCs (r 2 =0·40; P=0·03) in both untreated and treated diabetic men and the mean amount of IL-6 produced by CD33 hi myeloid DCs after stimulation with LPS plus IFN (r 2 =0·419; P=0·01) in type-2 diabetic men during treatment with testosterone.
Controls
Type-2 diabetic men
Discussion
In the present study we show for the first time that testosterone-replacement therapy in type-2 diabetic men with partial androgen deficiency is associated with an almost complete abrogation of spontaneous ex vivo secretion of the IL-, IL-6 and TNF inflammatory cytokines by both circulating PB monocytes and DCs. Interestingly, similar effects were observed for the various subsets of circulating APCs and the different inflammatory cytokines analyzed.
To date, few reports have analyzed the effects of androgen-replacement therapy on cytokine production in hypogonadal subjects. In this regard, it has been shown that androgen therapy in patients with Klinefelter's syndrome decreased the levels of serum IgA, IgG, IgM, IL-2 and IL-4 . Likewise, testosteronereplacement therapy in hypogonadal men has been shown to induce reductions in TNF and IL-1 serum levels, together with increased IL-10, in the absence of significant changes in the serum concentrations of IL-6 (Malkin et al. 2004) . In turn, gonadotropin treatment in patients with idiopathic hypogonadotropic hypogonadism, significantly decreased the production of IL-1 and TNF by stimulated PB mononuclear cells; this effect was associated with decreased serum levels of IL-2 and IL-4 and reduced PB counts of total lymphocytes, CD3+ and CD4+ T cells, CD19+ B cells and the CD4+/CD8+ ratio , Musabak et al. 2003 . In addition, it has been shown that acute hypogonadism induced in Table 4 In vitro-stimulated secretion of inflammatory cytokines by peripheral blood (PB) monocytes and dendritic cells (DCs) in type-2 diabetic patients with partial androgen deficiency before treatment and after 1, 3, 6 and 12 months of testosterone-replacement therapy (TX), in comparison to control subjects Type-2 diabetic men normal elderly men by administration of gonadotropinreleasing hormone (GnRH) has the opposite effect, increasing the circulating levels of TNF and IL-6. In turn, in these subjects subsequent transdermal testosterone therapy reduced the concentrations of TNF but not those of IL-6 (Kosla et al. 2002) . Our results confirm and expand these observations in that they show, in another model of human androgen deficiency, that androgenreplacement therapy depresses spontaneous ex vivo production of inflammatory cytokines by PB APCs. Interestingly, our results also indicate that depression of the production of proinflammatory cytokine associated with androgen therapy is not due to an exhaustion of the ability of these cells to produce these cytokines in diabetic men since stimulation of PB monocytes and DCs with LPS plus IFN induced fairly similar patterns of response to those observed in a group of age-matched healthy controls.
Little is known about the effects of androgen treatment on DC in humans. In this sense, Galasso et al. (1996) investigated the effects of topical application of testosterone propionate on the epidermal density of CD1+ DCs in a group of women, detecting a clear reduction of these cells. Likewise, in the mouse, systemic and topical application of testosterone significantly reduced the density of epidermal Langerhans cells (Koyama et al. 1989) .
In our patients, testosterone-replacement therapy could induce immunosuppressive effects through either direct or indirect mechanisms. Androgen receptors or their mRNA have been detected in both CD4+ and CD8+ T cells as well as in macrophages (Liva & Voskuhl 2001 , Tanriverdi et al. 2003 and it has been shown that testosterone may directly induce cytokine gene expression on CD4+ T lymphocytes via androgen receptors (Liva & Voskuhl 2001) . Monocyte-derived macrophages also express androgen receptors (McCrohon et al. 2000) and these cells may metabolize testosterone to 5 -dihydrotestosterone (Araneo et al. 1991) . In this regard, treatment of mice with flutamide, an androgen-receptor blocker, restores previously depressed cellular immunity after brain injury (Messingham et al. 2001) . However, to the best of our knowledge no study has been reported so far in which the expression of androgen receptors is analyzed in DCs. Therefore, the key premise for a direct action of androgens on these cells is currently lacking. In turn, GnRH has immunostimulatory effects (Tanriverdi et al. 2003) and it has been suggested that the immunosuppressive effects of androgens could be indirectly mediated by GnRH (Jacobson & Ansari 2004) . Thus, whereas androgens have suppressive effects on GnRH and gonadotropin secretion, estrogens enhance their secretion through a positivefeedback effect (Jacobson & Ansari 2004) . In line with this notion, plasma levels of LH showed a significant correlation with IL-6 secretion by both CD16+ DCs and CD33 hi myeloid DC in diabetic patients during treatment with testosterone. Another possibility could be related to the fact that the secretion of IL-1 and TNF is under the positive influence of IFN , as also seen in this study, and it has been shown that the production of IFN by immune cells is reduced by testosterone (Araneo et al. 1991) .
The anti-inflammatory effects of androgen therapy observed in our model may have both beneficial and deleterious effects. Regarding the former, a depression in proinflammatory cytokine secretion induced by androgens in DC may in turn alter the patterns of cytokine secretion by T cells and alter their ability to direct T-helper responses (Cua & Stohlman 1997 , Chang et al. 2000 . In this regard, it has been reported that sex steroids induce changes in cytokine secretion by APCs in mice (Wilcoxen et al. 2000) ; these changes polarize cytokine secretion by T cells towards a Th1 or Th2 pattern (Wilcoxen et al. 2000 , Lanzavecchia & Sallusto 2001 . A decrease in the production of Th1-associated cytokines (IL-1 , IL-6, IFN and TNF ) by immune cells may bias the balance towards a Th2 pattern (IL-4, IL-10, IL-12), which could protect subjects from autoimmune diseases (Dalal et al. 1997 , Liva & Voskuhl 2001 , whereas a predominance of Th1 cytokines would enhance susceptibility to developing autoimmune disorders (Bao et al. 2002) .
Since monocytes, DCs and the inflammatory cytokines they secrete play an important role in both the development of atheroma plaque and its stability (Hansson 2005) it could be speculated that a decrease in cytokine production might have anti-atheromatous effects. Therefore, the anti-inflammatory role of androgen-substitutive therapy in aging type-2 diabetic men with partial androgen deficiency, a condition associated with clinically evident atherosclerosis in humans (Fukui et al. 2003) , could have atheroprotective effects (Malkin et al. 2003) . In turn, a depressed immune response by APCs may be detrimental in terms of host defence. In this sense, it has been shown that females tolerate trauma hemorrhage and subsequent sepsis better than males (Schroder et al. 1998) .
In summary, our findings indicate that androgenreplacement therapy in aging type-2 diabetic men with clinical and biochemical androgen deficiency has immunosuppressive and anti-inflammatory effects on both circulating PB monocytes and DCs. The anti-inflammatory effects of androgens may contribute to our understanding of the well-known relative resistance of males to autoimmune diseases and the outcome of atherosclerosis, and at the same time they could contribute to explain the depressive effect of androgens on host cellular immunity. Our results add new information to a promising field related to autoimmune diseases, gender responses to inflammation/sepsis, atheromatosis and plaque stability.
